Logo Icon
OrthoLength Pro Clinical & Patient Community
Log in Register
MEDICAL DISCLAIMER: The information provided on OrthoLength Pro is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified orthopedic surgeon.
Fact Checked by Clinical Team Study Summary

How Genetics Influence Egg Production and Fat in Older Laying Hens – Key Findings

Hu
Hubert A, Degalez F, Bedere N,...
April 17, 2026
200 views
View on PubMed
6 min read 1,105 words genetic factors egg production aging hens Medically Reviewed

Overview

Recent research has shed light on the genetics of egg production in aging laying hens, revealing how lipid reserves and liver function impact both egg size and laying persistence. Understanding these genetic factors is essential for poultry producers seeking to maintain high productivity as hens age, and for veterinarians advising on nutritional and breeding strategies.

The study examined a large population of Rhode Island Red hens at 90 weeks of age, using high‑density SNP genotyping to map quantitative trait loci (QTL) linked to abdominal fat weight (AFW) and yolk percentage (YP). By integrating liver expression quantitative trait loci (eQTL) data, the researchers identified candidate genes that regulate lipid metabolism, egg weight (EW) and laying rate (LR).

What This Study Examined

The investigators performed genome‑wide association studies (GWAS) on 7,000 hens, refined the signals with linkage disequilibrium (LD) mapping, and cross‑referenced the findings with liver gene‑expression data. Traits measured included AFW, YP, EW, LR, liver weight (LW), blood glycaemia (GLY) and ketonemia (KET).

Why This Matters for Patients

For poultry producers (the "patients" of this research), the results provide actionable genetic markers that can be used in selective breeding programs to improve metabolic efficiency, reduce excessive fat deposition, and sustain egg production in older hens. Better genetic insight translates into healthier flocks, more consistent egg yields, and potentially lower feed costs.

Medical Background

Egg production relies on a complex interplay of lipid synthesis, transport, and deposition. The liver is the primary organ for synthesizing lipids, which are then allocated to the yolk or stored as abdominal fat. In older hens, the balance between these pathways can shift, leading to reduced egg size or laying frequency.

AFW reflects how much lipid is stored in the hen’s abdomen, while YP measures the proportion of the egg that is yolk – a direct indicator of lipid allocation to the egg. Elevated KET levels signal that the bird is mobilizing fat for energy, a state that may indicate metabolic stress.

How the Procedure Works

In a GWAS, each bird’s DNA is scanned for single‑nucleotide polymorphisms (SNP) across the genome. Statistical models associate each SNP with the measured traits (e.g., AFW, YP). LD‑based refinement narrows broad association signals to tighter genomic regions, while eQTL analysis links those regions to genes whose expression in the liver changes with the same genetic variants.

Who Is a Candidate?

The "candidates" for this type of genetic analysis are commercial laying hens, especially those approaching the end of their productive cycle (around 80‑100 weeks of age). The findings are most relevant to producers who employ systematic breeding and record‑keeping practices.

Clinical Summary

  • Procedure: Genome‑wide association study with LD refinement and liver eQTL integration
  • Typical Duration: Data collection spanned a single laying cycle; genotyping and analysis were completed within ~12 months
  • Recovery: Not applicable – no invasive procedure performed on the animals
  • Success Rate (general): High statistical power; heritability estimates for AFW (0.50) and YP (0.51) indicate strong genetic influence

Study Methodology

This investigation was a cross‑sectional GWAS performed on an experimental cohort of 7,000 Rhode Island Red hens, all genotyped with a 60K SNP array and imputed to ~600K markers. Phenotypic data (AFW, YP, EW, LR, LW, GLY, KET) were recorded at 90 weeks of age, a time point representing advanced laying stages.

Patient Selection Criteria

Hens were included if they were healthy, had complete production records, and were of the Rhode Island Red breed. Birds exhibiting severe disease, abnormal body condition, or incomplete data were excluded.

Outcome Measures

The primary outcomes were the heritability of AFW and YP, genetic correlations among the six measured traits, and the identification of genome‑wide significant QTLs. Secondary outcomes included the integration of liver eQTLs to prioritize candidate genes.

Results & Findings

The analysis demonstrated that both AFW and YP have high heritability (0.50 and 0.51, respectively), confirming a strong genetic component to lipid storage and yolk formation in older hens. Notably, AFW showed considerably greater phenotypic variability than the other traits, suggesting a larger pool of exploitable genetic variation.

Key Outcomes

  • Positive genetic correlations of AFW and YP with LR (0.26 and 0.27) indicate that greater lipid reserves support continued laying.
  • Negative correlations with EW (AFW: –0.15; YP: –0.54) reveal a trade‑off where higher lipid allocation to the yolk may reduce overall egg mass.
  • KET was negatively correlated with LR (–0.32) and LW (–0.29), suggesting that elevated ketone bodies are a marker of metabolic stress that can impair production.
  • A strong genetic correlation between LW and YP (0.48) underscores a shared genetic basis for hepatic lipid synthesis and yolk deposition.
  • GWAS identified several suggestive QTLs for AFW, YP, and related metabolic traits; LD‑based refinement and eQTL integration reduced the candidate gene list, highlighting key regulatory genes involved in lipid metabolism.

Complications & Risks

The study was observational and did not involve invasive procedures, so no direct animal‑related complications were reported. The primary limitation is the focus on a single breed and a single age point, which may limit broader applicability.

Key Takeaways for Patients

  • Genetic factors account for about half of the variation in abdominal fat and yolk composition in older hens.
  • Higher abdominal fat and yolk percentage are linked to better laying persistence but may reduce individual egg weight.
  • Elevated ketone levels (KET) signal metabolic stress and are associated with lower laying rates and smaller livers.
  • Selective breeding using the identified QTLs could improve metabolic efficiency and sustain egg production longer.
  • Ask your breeder or veterinarian about genetic screening tools that target the highlighted QTLs to optimize flock performance.

Frequently Asked Questions

What does a high heritability estimate mean for egg production?
It means that roughly 50% of the differences you see in traits like abdominal fat or yolk percentage are due to genetics, making them reliable targets for selective breeding.
Can I use these genetic findings to improve my flock’s performance?
Yes. By incorporating the identified QTL markers into breeding programs, you can select birds that balance fat storage and yolk quality, extending productive laying periods.
Why is ketonemia (KET) important for older hens?
KET reflects the level of circulating ketone bodies, which rise when hens rely heavily on fat for energy. High KET is linked to lower laying rates and may indicate metabolic stress.
Does more abdominal fat always mean better egg production?
Not necessarily. While more fat supports laying persistence, excessive fat can reduce feed efficiency and increase health risks. The goal is an optimal balance.
Are the results applicable to other breeds besides Rhode Island Red?
The study focused on one breed, so while the general principles likely hold, specific QTL effects may vary. Further research is needed for other commercial lines.

Source: PubMed / Europe PMC

More on: genetic factors egg production aging hens Last reviewed: September 27, 2026

Community Disclaimer

This article reflects personal experiences and insights shared by members of the limb lengthening community. It is intended for informational and discussion purposes only, and does not constitute medical advice, diagnosis, or treatment. Individual experiences may vary. Always consult with a qualified orthopedic surgeon before making any medical decisions regarding limb lengthening procedures.

Explore Related Research

Clinical Insight

One-Year Transcutaneous Tibial Nerve Stimulation (TTNS) Treatment Persistence in Lower Urinary Tract Dysfunction: Detailed Review of Clinical and Urodynamic Factors

Overview Transcutaneous Tibial Nerve Stimulation (TTNS) is an emerging, non‑surgical treatment option for patients suffering from Lower Urinary Tract Dysfunction (LUTD). LUTD encompasses a broad spectrum of symptoms such as urinary incontinence, urgency, frequency, nocturia, and voiding difficulty. These symptoms can arise from a variety of underlying mechanisms—detrusor overactivity, impaired sphincter coordination, or neurogenic injury—making individualized management essential. TTNS works by delivering a low‑frequency electrical stimulus to the posterior tibial nerve at the ankle. The tibial nerve shares spinal roots (S2‑S4) with the pelvic floor nerves that regulate bladder storage and emptying. By modulating these shared pathways, TTNS can suppress abnormal detrusor contractions and improve sphincter coordination, leading to reduced urgency, fewer leaks, and better overall bladder control. Because TTNS can be performed at home with a handheld, battery‑operated device, it offers a convenient alternative to more invasive neuromodulation techniques (e.g., percutaneous tibial nerve stimulation or sacral neuromodulation). However, the long‑term success of any home‑based therapy depends heavily on patient adherence, perceived benefit, and the presence of any adverse effects. The study summarized below was designed to quantify real‑world adherence (persistence) over a full year and to identify the clinical and urodynamic factors that predict whether a patient will continue the therapy. Medical Background TTNS is a non‑invasive treatment that involves stimulating the tibial nerve using a small, wearable device. This stimulation can help to regulate the micturition cycle and improve symptoms of LUTD. How the Procedure Works During TTNS, a disposable electrode pad is placed on the skin just behind the medial malleolus (the inner ankle bone). A gentle electrical current—typically 5 to 20 Hz, 0.5 mA–5 mA—is applied for roughly 20 minutes each day. The current travels proximally along the tibial nerve, ultimately reaching the sacral spinal cord segments that control bladder and urethral function. Most patients report a mild tingling sensation without pain, and the session can be performed while seated or lying down. Who Is a Candidate? TTNS is usually offered to adults who have persistent LUTD despite first‑line therapies such as behavioral modification, pelvic floor muscle training, or anticholinergic/β‑3 agonist medications. It is particularly attractive for: Patients with overactive bladder (OAB) symptoms who cannot tolerate pharmacologic side effects. Individuals with neurogenic bladder secondary to spinal cord injury, multiple sclerosis, Parkinson disease, or cauda equina syndrome. Those who prefer a home‑based, needle‑free approach to neuromodulation. Clinical Summary Procedure: TTNS involves stimulating the tibial nerve using a small portable device. Typical Duration: Treatment sessions typically last 20 minutes per day, five to seven days per week. Recovery: There is no downtime or recovery period required for TTNS. Success Rate (general): Reported response rates range from 45 % to 70 % in short‑term trials, with durability varying by underlying diagnosis. Study Methodology The investigation was a prospective, monocentric, observational cohort study carried out at the Research Institute of Neurological and Urological Pathology (RnIPH) between October 2022 and January 2024 (registry number RnIPH 2022‑109). The study adhered to the Declaration of Helsinki and received local ethics committee approval. All participants provided written informed consent before enrollment. Patient Selection Criteria Inclusion criteria required adults (≥18 years) with a documented diagnosis of LUTD—whether neurogenic or non‑neurogenic—who were prescribed TTNS by a urologist or neuro‑urologist and who agreed to initiate home‑based therapy. Exclusion criteria comprised any of the following: pregnancy, implanted electronic devices (e.g., pacemaker, spinal cord stimulator), active skin infection at the ankle site, uncontrolled diabetes with peripheral neuropathy prohibiting safe electrode placement, or inability to understand study questionnaires. From a pool of 78 screened individuals, 56 met all criteria and commenced TTNS. Baseline demographic and clinical data were collected, including age, sex, body‑mass index, comorbidities, underlying etiology of LUTD (neurological vs. non‑neurological), and prior therapies. Baseline Assessments All participants underwent a standardized work‑up consisting of: Urodynamic study (uroflowmetry, cystometry, pressure‑flow analysis) to characterize detrusor activity, sphincter function, and bladder capacity. Validated patient‑reported outcome measures (PROMs): Patient Global Impression of Severity (PGI‑S) – 0 (no symptoms) to 4 (very severe). Patient Global Impression of Improvement (PGI‑I) – –3 (much worse) to +3 (much improved). Urinary Symptom Profile (USP) – subscales for overactive bladder (USP‑OAB) and stress incontinence. QUALIVEEN‑Short Form (QSF) – health‑related quality‑of‑life score ranging 0–100. Follow‑Up Schedule Patients were instructed to perform TTNS daily at home for 20 minutes. Follow‑up visits (or remote telehealth assessments) were scheduled at 2–4 months (early assessment) and at 12 months (long‑term assessment). At each visit, the study team recorded whether the patient was still using the device (persistence), any adverse events, and repeated the PROMs. Persistence over time was visualized using Kaplan–Meier survival curves, and factors influencing discontinuation were explored with Cox proportional hazards regression, both unadjusted and multivariable models adjusting for age, sex, neurological etiology, baseline symptom severity, and device acquisition status (i.e., whether the patient purchased the device). Results & Findings Overall, 56 patients initiated TTNS therapy. The cohort’s mean age was 58 ± 14 years, with a slight female predominance (31 women, 55 %). Thirty‑two patients (57 %) had a neurological cause of LUTD (multiple sclerosis, spinal cord injury, Parkinson disease, or peripheral neuropathy), while 24 (43 %) had idiopathic or stress‑incontinence‑predominant LUTD. Persistence at 12 Months At the one‑year mark, 21 of the 56 participants (38 %) remained persistently using TTNS. Persistence differed markedly between sub‑groups: Neurological patients: 18/32 (56 %) remained on therapy. Non‑neurological patients: 3/24 (13 %) remained on therapy. Patients who purchased the device (device owners): 21/34 (62 %) persisted, compared with 0/22 (0 %) among those who borrowed or were provided a loaner device. The Kaplan–Meier curve demonstrated a median time to discontinuation of 5.2 months for the whole cohort, but the curve plateaued after 8 months for neurological patients, indicating a durable subgroup effect. Predictors of Persistence In multivariable Cox regression, two variables emerged as statistically significant independent predictors of longer persistence: Neurological etiology: Adjusted hazard ratio (HR) = 0.42 (95 % CI 0.18–0.99, p = 0.047). This indicates a 58 % reduction in the risk of discontinuation for patients with neurogenic LUTD. Lower symptom burden at 2–4 months: For each unit decrease in PGI‑S, the hazard of stopping treatment decreased by 15 % (adjusted HR = 0.85, p = 0.03). Likewise, a higher PGI‑I score (greater perceived improvement) was associated with a 22 % lower hazard (adjusted HR = 0.78, p = 0.01). Urodynamic findings added nuance: an overactive urethral sphincter (characterized by elevated urethral pressure during filling) was more common among neurological patients (p = 0.008) and among the persistent subgroup (p = 0.006). This suggests that patients with combined detrusor‑overactivity and sphincter‑hyperactivity may derive particular benefit from TTNS. Patient‑Reported Outcomes Across the entire cohort, early improvements (2–4 months) were modest but statistically significant: Mean PGI‑S decreased from 3.2 ± 0.6 at baseline to 2.5 ± 0.7 (p 

Read Full Summary →
Clinical Insight

Longitudinal Melanonychia & Nail Melanoma Risk: A 18‑Year Singapore Study Explained

Overview Over an 18‑year period (2004‑2021), researchers at Singapore’s National Skin Centre examined more than 1,500 patients with longitudinal melanonychia (LM) to determine how often the condition represented nail apparatus melanoma (NAM). The study found that 4% of biopsied LM lesions were NAM, and it identified age ≥ 50 years, blue‑collar occupations, and single‑digit involvement as key predictors of malignancy. This information is vital for anyone who notices a dark streak on a fingernail or toenail, especially adults over 50 or individuals whose work exposes them to trauma. What This Study Examined The investigators retrospectively reviewed records of patients who presented with LM, recorded demographic data, clinical features (such as border regularity, Hutchinson’s sign, and changes over time), and biopsy outcomes. Of the 274 patients referred for possible biopsy, 198 actually underwent a nail unit biopsy, allowing a detailed analysis of risk factors for NAM. Why This Matters for Patients Early detection of nail melanoma dramatically improves survival. Because LM is a common, often benign finding—especially in people with darker skin tones—knowing which features raise suspicion helps patients decide when to seek specialist evaluation and can prevent delayed diagnosis of a potentially lethal cancer. Medical Background Nail apparatus melanoma is a rare but aggressive form of skin cancer that originates in the nail matrix, nail bed, or surrounding skin. It frequently appears as a dark, linear stripe called longitudinal melanonychia. While many LM lesions are harmless (e.g., due to racial pigmentation or trauma), a subset represents melanoma that can invade deeper structures and spread if not treated promptly. How the Procedure Works When a suspicious LM lesion is identified, a dermatologist or hand surgeon may perform a nail unit biopsy. The procedure typically involves removing a small segment of the nail plate to expose the underlying matrix or nail bed, then excising a wedge‑shaped specimen for pathological analysis. The tissue is examined under a microscope for atypical melanocytes, dysplasia, or invasive cancer. Who Is a Candidate? Candidates for biopsy include anyone with LM that meets high‑risk criteria: age ≥ 50 years, a single digit affected (monodactylous), irregular borders, widening over time, nail plate destruction, ulceration of the nail bed, or a positive Hutchinson’s sign (pigmentation extending to the adjacent skin). Occupational exposure to repetitive trauma (e.g., construction, manufacturing) also raises suspicion. Clinical Summary Procedure: Nail unit biopsy (partial or total nail plate removal with matrix/nail bed sampling) Typical Duration: 15–30 minutes (outpatient setting) Recovery: 1–2 weeks for wound healing; temporary nail growth disturbance Success Rate (general): >90% diagnostic accuracy for detecting melanoma when appropriate criteria are met Study Methodology This was a retrospective observational study reviewing electronic medical records from 2004 to 2021. The investigators identified patients who presented with LM at the National Skin Centre, extracted demographic information (age, sex, ethnicity, occupation), clinical characteristics of the nail lesions, and biopsy results. Patient Selection Criteria All patients with a clinical diagnosis of LM were included. From this pool, those referred for possible biopsy (274 individuals) were evaluated, and 198 patients who actually underwent a biopsy formed the final analytic cohort. Outcome Measures The primary outcome was the presence of NAM (including melanoma in situ). Secondary outcomes included the association of demographic or lesion‑specific factors with malignancy and the incidence of post‑biopsy complications such as nail dystrophy. Results & Findings Among the 1,556 patients with LM, the majority were Chinese (80.7%), female (58.0%), and under 50 years of age (63.8%). Of the 198 biopsied lesions, 79.3% involved a single digit (monodactylous) and 54.0% displayed regular borders. Hutchinson’s sign was positive in 10.6% of cases, and one‑third (33.3%) showed an interval increase in width. Key Outcomes Eight cases of NAM (4.0% of biopsied lesions) were identified; three were melanoma in situ. All invasive NAM lesions demonstrated nail plate destruction, ulceration of the nail bed, and a positive Hutchinson’s sign. Age ≥ 50 years (p = .001) and blue‑collar occupation (p = .049) were significantly associated with malignancy. Post‑biopsy complications occurred in 20.7% of patients, with nail dystrophy being the most common adverse event. Complications & Risks Biopsy of the nail unit carries potential risks, including: Nail dystrophy: permanent irregularity or deformity of the nail plate (most frequent, seen in ~20% of biopsied patients). Infection: rare but possible; requires antibiotic therapy. Bleeding: minor oozing is typical; significant hemorrhage is uncommon. Pain or tenderness: usually resolves within a few days. Delayed nail regrowth: may take several months for a new nail to fully mature. These risks must be weighed against the benefit of early melanoma detection. Key Takeaways for Patients Most longitudinal melanonychia is benign, but a dark stripe in adults over 50 warrants closer evaluation. Blue‑collar workers should be especially vigilant because occupational trauma increases melanoma risk. Warning signs include nail plate thinning or destruction, ulceration of the nail bed, widening of the stripe, irregular borders, and Hutchinson’s sign. If any of these features are present, ask your dermatologist or hand surgeon about a nail unit biopsy. Discuss potential post‑procedure nail changes, including dystrophy, before deciding on a biopsy. Frequently Asked Questions What is longitudinal melanonychia and how can I tell if it’s dangerous? Longitudinal melanonychia is a dark line that runs lengthwise along the nail. It becomes concerning if the line widens, changes color, involves the nail bed, or is accompanied by Hutchinson’s sign. Is a nail biopsy painful? The procedure is performed under local anesthesia, so discomfort is minimal. Some soreness may be felt for a few days afterward. How long does it take for a new nail to grow after a biopsy? Fingernails grow about 3 mm per month and toenails about 1 mm per month, so full regrowth can take 4‑12 months depending on the digit. Can nail melanoma be treated if it’s found early? Yes. Early‑stage nail melanoma, especially melanoma in situ, can often be cured with surgical excision. Advanced disease may require wider surgery, immunotherapy, or targeted therapy. Should I be screened for nail melanoma if I have a family history of skin cancer? Individuals with a personal or family history of melanoma should have regular skin examinations, and any new or changing nail pigmented lesions should be evaluated promptly. (Source: PubMed / Europe PMC) Related Articles Radial Longitudinal Deficiency Treatment

Read Full Summary →